FDA Pulls Authorization for GSK-Vir’s COVID Therapy, Sotrovimab, as BA.2 Cases Rise
The U.S. health regulator said on Tuesday GlaxoSmithKline (GSK.L) and Vir Biotechnology's (VIR.O) antibody therapy was no longer authorized as a COVID-19 treatment, with data suggesting it was unlikely to…